TODAY'S MARKET INTELLIGENCE
Sinocell: Subsidiary SCTB10 Gets Clinical Trial Approval for Hemophilia A
English summary
Sinocell announced its controlling subsidiary received approval for SCTB10 injection clinical trials in hemophilia A. The product is a recombinant anti-FIXa/FX bispecific antibody, and a phase I/II study is approved.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence